ROFERON-A®Roferon-A®injection for subcutaneous
injection.lMEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug.
Solution for injection
EXCIPIENTS:May contain Benzyl alcohol
▶IntronA(Merck Sharp & Dohme Ltd)
Interferon alfa-2b 10 mega u per 1 mlIntronA 10 million units/ 1 ml
solution for injection vials| 1 vialPs
IntronA 25 million units/ 2. 5 ml solution for injection multidose vials|
1 vialP£ 103. 94
Interferon alfa-2b 15 mega u per 1 mlIntronA 18 million units/ 1. 2 ml
solution for injection multidose pens| 1 pre-filled disposable
injectionP£ 74. 83
Interferon alfa-2b 25 mega u per 1 mlIntronA 30 million
units/ 1. 2 ml solution for injection multidose pens| 1 pre-filled
disposable injectionP£ 124. 72
Interferon alfa-2b 50 mega u per 1 mlIntronA 60 million
units/ 1. 2 ml solution for injection multidose pens| 1 pre-filled
disposable injectionP£ 249. 45
▶Roferon-A(Roche Products Ltd)
Interferon alfa-2a 6 mega u per 1 mlRoferon-A 3 million
units/ 0. 5 ml solution for injection pre-filled syringes| 1 pre-filled
disposable injectionP£ 14. 20
Interferon alfa-2a 9 mega u per 1 mlRoferon-A 4. 5 million
units/ 0. 5 ml solution for injection pre-filled syringes| 1 pre-filled
disposable injectionP£ 21. 29
Interferon alfa-2a 12 mega u per 1 mlRoferon-A 6 million
units/ 0. 5 ml solution for injection pre-filled syringes| 1 pre-filled
disposable injectionP£ 28. 37
Interferon alfa-2a 18 mega u per 1 mlRoferon-A 9 million
units/ 0. 5 ml solution for injection pre-filled syringes| 1 pre-filled
disposable injectionP£ 42. 57Interferon gamma-1b
(Immune interferon)
lINDICATIONS AND DOSE
To reduce the frequency of serious infection in chronic
granulomatous disease
▶BY SUBCUTANEOUS INJECTION
▶Child 6 months–17 years (body surface area up to
0.6 m^2 ): 1. 5 micrograms/kg 3 times a week
▶Child 6 months–17 years (body surface area 0.6 m^2 and
above): 50 micrograms/m^23 times a week
To reduce the frequency of serious infection in severe
malignant osteopetrosis
▶BY SUBCUTANEOUS INJECTION
▶Child (body surface area up to 0.6 m^2 ): 1. 5 micrograms/kg
3 times a week
▶Child (body surface area 0.6 m^2 and
above): 50 micrograms/m^23 times a weeklCONTRA-INDICATIONSSimultaneous administration of
foreign proteins including immunological products (such
as vaccines)—risk of exaggerated immune response
lCAUTIONSArrhythmias.cardiac disease.congestive heart
failure.ischaemia.seizure disorders (including seizures
associated with fever)
lSIDE-EFFECTS
▶Common or very commonAbdominal pain.arthralgia.back
pain.chills.depression.diarrhoea.fatigue.fever.
headache.nausea.rash.vomiting
▶Frequency not knownAtrioventricular block.chest
discomfort.confusion.connective tissue disorders.
embolism and thrombosis.gait abnormal.gastrointestinal
haemorrhage.hallucination.heart failure.hepatic failure
.hypertriglyceridaemia.hypoglycaemia.hyponatraemia.
hypotension.influenza like illness.myocardial infarction.
neutropenia.pancreatitis.parkinsonism.proteinuria.
renal failure.respiratory disorders.seizure.syncope.systemic lupus erythematosus (SLE).tachycardia.
thrombocytopenia.transient ischaemic attack
lCONCEPTION AND CONTRACEPTIONEffective
contraception required during treatment—consult product
literature.
lPREGNANCYManufacturers recommend avoid unless
potential benefit outweighs risk (toxicity inanimal
studies).
lBREAST FEEDINGManufacturers advise avoid—no
information available.
lHEPATIC IMPAIRMENTManufacturer advises caution in
severe impairment—risk of accumulation.
lRENAL IMPAIRMENTManufacturer advises caution in
severe impairment—risk of accumulation.
lMONITORING REQUIREMENTSMonitor before and during
treatment: haematological tests (including full blood
count, differential white cell count, and platelet count),
blood chemistry tests (including renal and liver function
tests) and urinalysis.lMEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug.
Solution for injection
▶Immukin(Horizon Pharma Ireland Ltd)
Interferon gamma-1b (recombinant human) 200 microgram per
1mlImmukin 100 micrograms/ 0. 5 ml solution for injection vials|
6 vialP£ 450. 00IMMUNOSTIMULANTS›OTHER
Mifamurtide
lINDICATIONS AND DOSE
Treatment of high-grade, resectable, non-metastatic
osteosarcoma after complete surgical resection (in
combination with chemotherapy)
▶BY INTRAVENOUS INFUSION
▶Child 2–17 years:Infusion to be given over 1 hour
(consult product literature or local protocols)lUNLICENSED USENot licensed for use in patients under
2 years of age at initial diagnosis.
lCAUTIONSAsthma—consider prophylactic bronchodilator
therapy.chronic obstructive pulmonary disease—consider
prophylactic bronchodilator therapy.history of
autoimmune disease.history of collagen disease.history
of inflammatory disease
lINTERACTIONS→Appendix 1 : mifamurtide
lSIDE-EFFECTS
▶Common or very commonAlopecia.anaemia.anxiety.
appetite decreased.arthralgia.asthenia.cancer pain.
chest discomfort.chills.confusion.constipation.cough.
cyanosis.dehydration.depression.diarrhoea.dizziness.
drowsiness.dysmenorrhoea.dyspnoea.feeling cold.
fever.flushing.gastrointestinal discomfort.haemorrhage
.headache.hearing impairment.hepatic pain.
hyperhidrosis.hypertension.hypokalaemia.hypotension
.hypothermia.increased risk of infection.insomnia.
laryngeal pain.leucopenia.malaise.mucositis.muscle
complaints.musculoskeletal stiffness.nasal congestion.
nausea.neutropenia.oedema.pain.palpitations.
respiratory disorders.sensation abnormal.sepsis.skin
reactions.tachycardia.thrombocytopenia.tremor.
urinary disorders.vascular disorders.vertigo.vision
blurred.vomiting.weight decreased
lCONCEPTION AND CONTRACEPTIONEffective
contraception required.
lPREGNANCYAvoid.
lBREAST FEEDINGAvoid—no information available.558 Immunotherapy responsive malignancy BNFC 2018 – 2019
Immune system and malignant disease8